Form 4: Macrogenics VP Granted 25,000 Stock Options

Macrogenics' VP, Controller & Treasurer, Beth Ann Smith, was granted 25,000 employee stock options with a $1.33 exercise price.

Summary

• Beth Ann Smith, VP, Controller & Treasurer of Macrogenics Inc. (MGNX), was granted 25,000 employee stock options.
• The options have an exercise price of $1.33 per share.
• The grant date for these options was December 8, 2025, and they expire on December 8, 2035.
• The options will vest over time, with 25% vesting one year from the grant date and the remaining 75% vesting in 12 substantially equal quarterly installments thereafter.
• This transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 7

Explanation: The grant of stock options is a positive for executive retention and alignment with shareholder interests, reflecting standard compensation practices. It's not a direct financial performance indicator but a routine governance item.

Positives

• The grant of stock options aligns management's interests with shareholder value creation, incentivizing long-term performance.
• The options have a 10-year expiration period, providing a significant window for potential value realization.
• The transaction was executed under a Rule 10b5-1 plan, indicating a pre-arranged, compliant transaction.

Negatives

• The exercise price of $1.33 indicates that the stock price must rise above this level for the options to have intrinsic value, representing a potential future dilution if exercised.

Risks

• The value of the stock options is entirely dependent on the future performance of Macrogenics' stock price. If the stock price does not exceed the exercise price of $1.33, the options may expire worthless.
• Future stock price volatility could impact the perceived value and potential gains from these options.

Future Outlook

The options are structured to vest over a period of approximately four years (one year for 25%, then 12 quarterly installments for 75%), indicating a long-term incentive for the executive to contribute to the company's sustained growth and stock performance.

Industry Context

Granting stock options to key executives is a standard practice in the biotechnology and pharmaceutical industries, as well as other growth sectors, to attract, retain, and incentivize talent. It aligns executive compensation with long-term shareholder value creation, particularly in companies like Macrogenics that may have significant future growth potential tied to drug development and commercialization.

Comparison to Industry Standards

• The grant of 25,000 options to a VP-level executive is a common form of equity compensation, comparable to practices at similar-sized biotech firms.
• The 10-year expiration period is standard for employee stock options across many industries.
• The vesting schedule, with an initial one-year cliff followed by quarterly vesting, is a typical structure designed to encourage long-term employee retention and performance, similar to companies like Amgen or Gilead Sciences for their executive compensation packages.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also potential for increased shareholder value if the options incentivize strong company performance.
• Employees: Reinforces the company's commitment to executive compensation and retention, potentially signaling stability in leadership.

Next Steps

• The options will begin to vest one year from the grant date (December 8, 2026).
• The remaining 75% of options will vest in 12 substantially equal quarterly installments thereafter.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event (stock option grant) and does not provide new information about the company's operational or financial performance that would warrant a change in investment recommendation. It's a standard governance disclosure.

Keywords

Macrogenics, MGNX, Stock Options, Form 4, Insider Transaction, Executive Compensation, Equity Grant, Rule 10b5-1